Icon Plc - ICLR STOCK NEWS

ICON plc (NASDAQ: ICLR) reported its Q1 2023 financial results with net business wins of $2,415 million and a book-to-bill ratio of 1.22. Revenues reached $1,978.6 million, up 4.0% year-over-year. The adjusted EBITDA stood at $399.1 million, 20.2% of revenue, reflecting a 17.2% increase. GAAP net income was $116.7 million, or $1.41 per share. The company reaffirmed its full-year 2023 revenue guidance in the range of $7,940 - $8,340 million and adjusted EPS guidance of $12.40 - $13.05, indicating a year-on-year growth of 5.5% to 11.1%. Cash flow from operations amounted to $175.5 million, with a net debt of $4.2 billion and a debt-to-adjusted EBITDA ratio of 2.8x.

ICON plc (NASDAQ: ICLR) has announced that it will release its financial results for Q1 2023 after market close on April 26, 2023. A conference call and webcast to discuss these results will occur on April 27, 2023, at 8:00 AM ET. The company, headquartered in Dublin, employs approximately 41,100 people across 111 locations in 53 countries, focused on healthcare intelligence and clinical research.

The press release emphasizes the importance of these financial results and cautions that forward-looking statements are subject to risks and uncertainties, including the impact of COVID-19 and market conditions.

LEO Pharma and ICON plc (NASDAQ: ICLR) have announced a strategic partnership aimed at enhancing patient-centric clinical trial execution. This initiative, dubbed PACE, seeks to address current clinical development challenges by improving access to innovative dermatology treatments. The partnership will utilize a hybrid outsourcing model, allowing for scalable efficiencies in clinical trials, decentralized clinical trials, and leveraging ICON's extensive resources. This collaboration aligns with LEO Pharma's 2030 strategy, focusing on delivering treatments faster and supporting sustainable business practices.

ICON plc (NASDAQ: ICLR), a leading clinical research organization, announced that CFO Brendan Brennan will present at the 2023 Citi Healthcare Conference on March 2, 2023, at 2pm ET. Additionally, CEO Steve Cutler will present at the Barclays Global Healthcare Conference on March 15, 2023, starting at 1:35pm ET. Both presentations will be available via live webcast, with links posted on ICON's investor relations website. As of December 31, 2022, ICON employed approximately 41,100 staff across 111 locations in 53 countries, focused on advancing clinical research for various healthcare sectors.

ICON plc (NASDAQ: ICLR) reported robust financial results for Q4 2022 and the full year, showcasing strong operational performance. Net business wins were $2,350 million in Q4, with a record backlog of $20.7 billion, reflecting a 2.4% quarterly increase. Q4 revenue reached $1,962 million, a 4.3% rise from the previous year. Full-year revenue was $7,741.4 million, a significant 41.2% growth. Adjusted EBITDA for Q4 was $405 million, marking a 21.8% increase, while GAAP net income for the full year amounted to $505.3 million, translating to $6.13 per diluted share. The company reaffirmed its 2023 revenue guidance of $7,940 - $8,340 million.

ICON (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, will release its financial results for Q4 2022 on February 22, 2023, after market close. A conference call to discuss the results will be held on February 23, 2023, at 8:00 am ET. The company, headquartered in Dublin, Ireland, employed approximately 41,150 employees across 113 locations in 53 countries as of September 30, 2022. Investors are advised that this release contains forward-looking statements subject to risks and uncertainties, and should not rely solely on them for investment decisions.